INZY Insider Trading (Inozyme Pharma)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $13,000,000.00

Insider Selling (Last 12 Months): $7,875,000.00

Inozyme Pharma Insider Trading History Chart

Inozyme Pharma Share Price & Price History

^$19.02

▼ -0.26 (-1.35%)

As of 04/9/2021 01:00 AM ET

Days: 30 | 90 | 365

Get out of cash NOW

From True Market Insiders | Ad

Millionaire Wall Street Legend Urges Americans To Get Out Of CASH before April 27th.

Details here.

Inozyme Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/28/2021	Holdings A/S Novo	Major Shareholder	Sell	375,000	$21.00	$7,875,000.00	2,194,379
7/28/2020	Longitude Capital Partners Iii	Major Shareholder	Buy	625,000	$16.00	$10,000,000.00
7/28/2020	Robert Lorne Hopfner	Director	Buy	187,500	$16.00	$3,000,000.00

SEC Filings (Institutional Ownership Changes) for Inozyme Pharma (NASDAQ:INZY)

69.77% of Inozyme Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inozyme Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/12/2021	DekaBank Deutsche Girozentrale	7,000	$0.17M	0.0%	N/A	0.030%
2/19/2021	JPMorgan Chase & Co.	3,836	$79K	0.0%	+26.6%	0.016%
2/16/2021	Baker BROS. Advisors LP	106,999	$2.21M	0.0%	-9.7%	0.458%
2/16/2021	Nuveen Asset Management LLC	21,292	$0.44M	0.0%	+24.7%	0.091%
2/16/2021	Avidity Partners Management LP	9,683	$0.20M	0.0%	-84.3%	0.041%
2/16/2021	Charles Schwab Investment Management Inc.	49,045	$1.01M	0.0%	+1.5%	0.210%
2/12/2021	CHI Advisors LLC	995,396	$20.55M	5.8%	-1.4%	4.259%
2/11/2021	Citigroup Inc.	2,236	$46K	0.0%	+473.3%	0.010%
2/9/2021	Wells Fargo & Company MN	9,696	$0.20M	0.0%	+58.6%	0.041%
2/9/2021	Pivotal bioVenture Partners Investment Advisor LLC	1,591,154	$32.84M	10.8%	N/A	6.808%
2/9/2021	Bank of New York Mellon Corp	21,349	$0.44M	0.0%	+10.1%	0.091%
2/8/2021	New York State Common Retirement Fund	7,400	$0.15M	0.0%	N/A	0.032%
2/5/2021	BlackRock Inc.	630,751	$13.02M	0.0%	+25.9%	2.699%
2/4/2021	State of Wisconsin Investment Board	11,400	$0.24M	0.0%	N/A	0.049%
12/30/2020	Deerfield Management Company L.P. Series C	1,150,299	$30.24M	0.6%	N/A	4.921%
12/14/2020	Strs Ohio	2,000	$52K	0.0%	N/A	0.009%
11/17/2020	California State Teachers Retirement System	12,298	$0.32M	0.0%	N/A	0.053%
11/16/2020	State of Tennessee Treasury Department	9,044	$0.24M	0.0%	N/A	0.039%
11/13/2020	Morgan Stanley	1,251	$33K	0.0%	N/A	0.005%
11/13/2020	Charles Schwab Investment Management Inc.	48,334	$1.27M	0.0%	N/A	0.207%
11/13/2020	Sofinnova Investments Inc.	2,028,308	$53.32M	4.0%	N/A	8.681%
11/12/2020	JPMorgan Chase & Co.	3,029	$72K	0.0%	N/A	0.013%
11/12/2020	Yale University	113,502	$2.98M	9.1%	N/A	0.486%
11/12/2020	Sphera Funds Management LTD.	196,411	$5.16M	0.5%	N/A	0.841%
11/10/2020	State Street Corp	70,585	$1.86M	0.0%	N/A	0.302%
11/6/2020	NEA Management Company LLC	2,444,379	$64.26M	2.7%	N/A	10.462%
11/6/2020	BlackRock Inc.	500,934	$13.17M	0.0%	N/A	2.144%
11/5/2020	California Public Employees Retirement System	16,011	$0.42M	0.0%	N/A	0.069%

Data available starting January 2016

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $19.02

$18.74

$19.37

50 Day Range

MA: $20.28

$17.77

$22.14

52 Week Range

Now: $19.02

$16.10

$31.65

Volume

16,195 shs

Average Volume

63,536 shs

Market Capitalization

$446.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Inozyme Pharma?

Inozyme Pharma's top insider investors include:

Holdings A/S Novo (Major Shareholder)
Longitude Capital Partners Iii (Major Shareholder)
Robert Lorne Hopfner (Director)